Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

59.43
Delayed Data
As of Dec 02
 +0.27 / +0.46%
Today’s Change
50.71
Today|||52-Week Range
68.12
+0.32%
Year-to-Date
FDA Orphan Drug Designation for AbbVie's Risankizumab
Dec 01 / GuruFocus News - Paid Partner Content
Big Pharma healthcare R&D steps out into the open
Nov 29 / FT.com - Paid Partner Content
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
Dec 01 / Zacks.com - Paid Partner Content
3 Top Drug Stocks for Your Retirement Portfolio
Nov 28 / MotleyFool.com - Paid Partner Content
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar
Nov 30 / GuruFocus News - Paid Partner Content
J&J confirms talks with Actelion over pharma deal
Nov 25 / FT.com - Paid Partner Content
Momenta/Shire's Humira Biosimilar Meets Study Objective
Nov 30 / Zacks.com - Paid Partner Content
Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
Nov 23 / Zacks.com - Paid Partner Content
Why the $324 Billion Bioeconomy Deserves a Place in Your Portfolio
Nov 30 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Nov 21 / Zacks.com - Paid Partner Content
Testing of Treatment for Cystic Fibrosis Patients Begins
Nov 29 / GuruFocus News - Paid Partner Content
US stocks defy fears of panic with steady open after Trump win
Nov 09 / FT.com - Paid Partner Content
Healthcare Stocks Help Nasdaq Reach New Heights
Nov 29 / TheStreet.com - Paid Partner Content